Dr. Ruth M. Risueño

Co-Founder & CSO

Therapeutic Areas

Drug	Indication	Phase
LB208	Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Triple-Negative Breast Cancer (TNBC), Hepatocellular Carcinoma (HCC), Ovarian Cancer	Pre-clinical